Table 3.

Predictors of Parkinson’s disease dementia

	Baseline variable	Univariable analysis		Multivariable analysis
		HR (95% CI)	p Value	HR (95% CI)	p Value
Model 1a (N = 196)	Age (10-year increase)	2.17 (1.67–2.81)	< 0.001	2.36 (1.72–3.25)	< 0.001
	Male vs female sex	1.03 (0.68–1.55)	0.91	0.74 (0.48–1.16)	0.19
	Years of education	0.94 (0.87–1.02)	0.14	1.05 (0.97–1.14)	0.23
	Smoking
	Ex vs never	1.36 (0.54–3.43)	0.51	1.24 (0.47–3.29)	0.67
	Current vs never	1.74 (1.13–2.67)	0.01	1.16 (0.73–1.83)	0.53
	BMI	0.96 (0.91–1.01)	0.12	0.97 (0.90–1.04)	0.36
	History of vascular disease or diabetes	1.28 (0.83–2.00)	0.27	0.71 (0.44–1.15)	0.16
	History of cognitive symptoms	2.31 (1.41–3.78)	0.001	1.98 (1.16–3.40)	0.01
	History of dream enactment symptoms	2.24 (1.38–3.65)	0.001	2.63 (1.54–4.49)	< 0.001
	MMSE	0.85 (0.80–0.91)	< 0.001	0.89 (0.81–0.98)	0.02
	UPDRS part 3 (motor) (10-unit increase)	1.41 (1.19–1.68)	< 0.001	1.01 (0.99–1.03)	0.23
Model 2b (N = 128)	NART	0.99 (0.96–1.02)	0.67	1.01 (0.97–1.05)	0.64
	GDS-15	1.02 (0.94–1.09)	0.68	0.98 (0.89–1.08)	0.64
	MMP	0.90 (0.85–0.96)	0.001	0.93 (0.86–1.02)	0.12
Model 3c (N = 141)	Any GBA variant	1.03 (0.51–2.10)	0.93	1.75 (0.81–3.75)	0.15
	MAPT H1/H1 haplotype	0.80 (0.48–1.35)	0.41	0.63 (0.36–1.09)	0.10
	ApoE ε4 carrier	1.82 (1.11–2.98)	0.02	3.12 (1.66–5.87)	< 0.001

ApoE apolipoprotein E, BMI body mass index, CI confidence interval, GBA glucocerebrosidase, GDS-15 Geriatric Depression Scale-15 item, HR hazards ratio, MAPT microtubule-associated protein tau, MMSE mini-mental state examination, MMP mini-mental Parkinson’s, NART National adult reading test, UPDRS Unified Parkinson’s Disease Rating Scale

^aMultivariable analysis adjusted for all other variables listed in model 1

^bMultivariable analysis adjusted for all variables listed in model 1 except years of education and MMSE

^cMultivariable analysis adjusted for all variables listed in model 1